Purple Biotech Ltd
PPBT
$2.30
$0.0251.10%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | 196.00K | 196.00K | |
| Gross Profit | -- | -- | -196.00K | -196.00K | |
| SG&A Expenses | -- | -- | 3.90M | 4.46M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 19.74M | 21.62M | |
| Operating Income | -- | -- | -19.74M | -21.62M | |
| Income Before Tax | -- | -- | -16.11M | -18.86M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -16.11 | -18.86 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | 79.00K | 91.00K | |
| Net Income | -- | -- | -16.03M | -18.76M | |
| EBIT | -- | -- | -19.74M | -21.62M | |
| EBITDA | -- | -- | -19.58M | -21.45M | |
| EPS Basic | -- | -- | -0.06 | -0.08 | |
| Normalized Basic EPS | -- | -- | -0.02 | -0.03 | |
| EPS Diluted | -- | -- | -0.06 | -0.08 | |
| Normalized Diluted EPS | -- | -- | -0.02 | -0.03 | |
| Average Basic Shares Outstanding | -- | -- | 1.02B | 957.46M | |
| Average Diluted Shares Outstanding | -- | -- | 1.02B | 957.46M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |